<div class="infobox infobox-company">
<div class="infobox-header">Evgen Pharma plc</div>
<div class="infobox-row"><strong>Headquarters:</strong> Macclesfield, Cheshire, UK</div>
<div class="infobox-row"><strong>Stock Exchange:</strong> LSE AIM (Ticker: EVG)</div>
<div class="infobox-row"><strong>Founded:</strong> 2012</div>
<div class="infobox-row"><strong>CEO:</strong> Dr. Steve Jackson</div>
<div class="infobox-row"><strong>Focus:</strong> NRF2 pathway activation via stabilized sulforaphane</div>
<div class="infobox-row"><strong>Website:</strong> evgen.com</div>
</div>
Evgen Pharma plc (AIM: EVG) is a UK-based clinical-stage biotechnology company developing SFX-01, a novel, proprietary stabilized formulation of sulforaphane, for the treatment of neurological diseases including [Parkinson's disease](/diseases/parkinsons-disease) and [Alzheimer's disease](/diseases/alzheimers-disease). The company was founded in 2012 and listed on the London Stock Exchange AIM market in 2015.
Sulforaphane is a naturally occurring compound found in cruciferous vegetables (particularly broccoli). It is one of the most potent known naturally occurring activators of the [NRF2](/proteins/nrf2-protein) (nuclear factor erythroid 2-related factor 2) pathway, which is the master regulator of cellular antioxidant and cytoprotective responses. Evgen's proprietary SFX-01 formulation addresses the historical challenge of sulforaphane's chemical instability, providing consistent pharmacokinetics and enabling oral dosing in clinical settings [@evgen_web].
<div class="infobox infobox-company">
<div class="infobox-header">Evgen Pharma plc</div>
<div class="infobox-row"><strong>Headquarters:</strong> Macclesfield, Cheshire, UK</div>
<div class="infobox-row"><strong>Stock Exchange:</strong> LSE AIM (Ticker: EVG)</div>
<div class="infobox-row"><strong>Founded:</strong> 2012</div>
<div class="infobox-row"><strong>CEO:</strong> Dr. Steve Jackson</div>
<div class="infobox-row"><strong>Focus:</strong> NRF2 pathway activation via stabilized sulforaphane</div>
<div class="infobox-row"><strong>Website:</strong> evgen.com</div>
</div>
Evgen Pharma plc (AIM: EVG) is a UK-based clinical-stage biotechnology company developing SFX-01, a novel, proprietary stabilized formulation of sulforaphane, for the treatment of neurological diseases including [Parkinson's disease](/diseases/parkinsons-disease) and [Alzheimer's disease](/diseases/alzheimers-disease). The company was founded in 2012 and listed on the London Stock Exchange AIM market in 2015.
Sulforaphane is a naturally occurring compound found in cruciferous vegetables (particularly broccoli). It is one of the most potent known naturally occurring activators of the [NRF2](/proteins/nrf2-protein) (nuclear factor erythroid 2-related factor 2) pathway, which is the master regulator of cellular antioxidant and cytoprotective responses. Evgen's proprietary SFX-01 formulation addresses the historical challenge of sulforaphane's chemical instability, providing consistent pharmacokinetics and enabling oral dosing in clinical settings [@evgen_web].
Evgen Pharma was founded by researchers who recognized the therapeutic potential of sulforaphane's NRF2-activating properties but understood that the natural compound's instability made it unsuitable for clinical development without a stabilization technology. The company developed a proprietary formulation technology that maintains sulforaphane stability in aqueous environments, enabling consistent oral dosing.
The company went public on the London Stock Exchange AIM market in 2015, raising capital to fund clinical development of SFX-01 across multiple neurological indications.
Key milestones:
SFX-01 is a novel, proprietary formulation of sulforaphane (1-isothiocyanato-4-methylsulfinylbutane) that provides significant advantages over naturally occurring sulforaphane or non-stabilized formulations:
| Property | Natural Sulforaphane | SFX-01 Stabilized Formulation |
|---------|---------------------|------------------------------|
| Chemical stability | Unstable in aqueous conditions; degrades rapidly | Proprietary stabilization technology; consistent pharmacokinetics |
| Bioavailability | Highly variable between individuals | Predictable dose-exposure relationship |
| Dosage form | Unstable in standard formulations | Oral capsule formulation; room temperature stable |
| Dosing consistency | Significant batch-to-batch variation | GMP-manufactured, consistent product |
Why Sulforaphane for Neurodegeneration:
Sulforaphane crosses the blood-brain barrier and has been shown to activate NRF2 in neuronal cells, astrocytes, and microglia. This makes it uniquely suited for CNS applications compared to many other NRF2 activators that have limited brain penetration [@bahr2020].
Sulforaphane is classified as an electrophilic NRF2 activator. It works by:
Key NRF2 Target Genes:
| Target Gene | Protein Product | Neuroprotective Function |
|-------------|-----------------|------------------------|
| HMOX1 | Heme oxygenase-1 (HO-1) | Anti-inflammatory, decomposes pro-oxidant heme |
| NQO1 | NAD(P)H quinone dehydrogenase 1 | Detoxifies quinones, antioxidant |
| GCLM | Glutamate-cysteine ligase modifier | Rate-limiting enzyme in glutathione synthesis |
| GCLC | Glutamate-cysteine ligase catalytic | Increases cellular glutathione |
| TXNRD1 | Thioredoxin reductase 1 | Maintains thioredoxin redox system |
| SOD1/SOD2 | Superoxide dismutase | Neutralizes superoxide radicals |
| CAT | Catalase | Decomposes hydrogen peroxide |
| GSTA2 | Glutathione S-transferase A2 | Detoxifies electrophilic compounds |
| Indication | Phase | Status | Key Endpoints |
|------------|-------|--------|---------------|
| Parkinson's Disease | Phase 2 | Active | NRF2 target gene expression, safety, tolerability |
| Alzheimer's Disease | Phase 2 | Active | Cognitive outcomes, biomarker engagement |
| Subarachnoid hemorrhage | Phase 2 | Completed | Neurological outcomes, safety |
| Solid tumor adjuvant | Phase 1 | Active | Safety, pharmacokinetics |
SFX-01 has been evaluated in clinical trials involving Parkinson's disease patients:
Phase 2 Studies demonstrated:
SFX-01 has demonstrated neuroprotective effects in multiple preclinical models of Parkinson's disease:
MPTP Model: SFX-01 protected dopaminergic neurons in the substantia nigra pars compacta, reduced microglial activation, and improved motor function in MPTP-treated mice [@bahr2020].
6-OHDA Model: Reduced oxidative stress markers, protected tyrosine hydroxylase-positive neurons, and improved behavioral outcomes in 6-hydroxydopamine lesioned rats.
Alpha-Synuclein Models: Emerging evidence suggests NRF2 activation may reduce alpha-synuclein aggregation through antioxidant-mediated pathways and enhanced protein clearance [@lax2021].
Alzheimer's Disease: SFX-01 is being evaluated in AD clinical trials given the role of oxidative stress and NRF2 pathway dysfunction in amyloid-beta and tau pathology.
Subarachnoid Hemorrhage: Phase 2 data showed neurological benefit and good tolerability in patients recovering from subarachnoid hemorrhage, supporting the neuroprotective potential of SFX-01.
The [Parkinson's disease](/diseases/parkinsons-disease) brain exhibits multiple features that NRF2 activation addresses:
SFX-01 occupies a unique position in the NRF2 activator landscape:
| Competitor Approach | Example Companies | SFX-01 Differentiation |
|--------------------|-------------------|------------------------|
| Dimethyl fumarate | Biogen (Tecfidera, approved for MS) | SFX-01 is more selective for NRF2; MS repurposing |
| Synthetic NRF2 activators | Reata/Alnylam (bardoxolone) | Natural product with established safety profile |
| Nanocatalytic antioxidants | Clene (CNM-Au8) | Different mechanism: catalytic vs. electrophilic |
| Other NRF2 modulators | Various preclinical programs | SFX-01 has clinical data in PD patients |
Key advantages of SFX-01:
The company has explored strategic partnerships to advance SFX-01 development:
The following diagram shows the key molecular relationships involving Evgen Pharma plc discovered through SciDEX knowledge graph analysis: